Industry
Biotechnology
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Avi Kapoor
August 19, 2024 | 5:37 pm
Portfolio Pulse from Avi Kapoor
August 19, 2024 | 2:25 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 10:44 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 10:40 am
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 5:45 pm
Portfolio Pulse from Benzinga Newsdesk
July 26, 2024 | 3:44 pm
Portfolio Pulse from Benzinga Newsdesk
July 25, 2024 | 12:37 pm
Portfolio Pulse from Benzinga Newsdesk
July 02, 2024 | 2:37 pm
Portfolio Pulse from Benzinga Newsdesk
July 02, 2024 | 12:34 pm
Portfolio Pulse from Benzinga Newsdesk
July 02, 2024 | 12:33 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.